Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
NCT03935256
Active Not Recruiting
The purpose of this trial is to evaluate the safety of sequential and concurrent carboplatin and paclitaxel with adjuvant external beam radiotherapy for locally advanced endometrial cancer. The primary objective is to assess the acute toxicities namely grade 3-4 non hematologic and grade 4 hematologic toxicities associated with the above regimen. The null hypothesis is that the unacceptable toxic response rate is ≥40%. This will be tested against a one-sided alternative that the toxicity rate is... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: Loyola University Medical Center, Marywood, Illinois
Conditions: Endometrial Cancer
Register for Updates
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
NCT03415854
Completed
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2023
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases, Adenocarcinoma
Register for Updates
A Study of ABT-165 in Subjects With Solid Tumors
NCT01946074
Completed
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and irinotecan (FOLFIRI) or ABBV-181 with/without paclitaxel in subjects with advanced solid tumors. Enrollment to Cohorts A, B were completed and for Cohorts C and D are recruiting.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/13/2023
Locations: HonorHealth Research Institute - Pima /ID# 105677, Scottsdale, Arizona +9 locations
Conditions: Advanced Solid Tumors
Register for Updates
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
NCT02621398
Active Not Recruiting
This phase I trial studies the side effects, best dose, and best way to give pembrolizumab when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-IIIB non-small cell lung cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by sto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: Yale Cancer Center, New Haven, Connecticut +2 locations
Conditions: Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Register for Updates
Study of ORIC-101 in Combination With Anticancer Therapy
NCT03928314
Terminated
The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with nab-paclitaxel or other anticancer therapies when administered to patients with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: Stanford Cancer Institute, Palo Alto, California +11 locations
Conditions: Solid Tumor
Register for Updates
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
NCT00679029
Terminated
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab ma... Read More
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
12/07/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Register for Updates
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
NCT02887248
Terminated
The purpose of this trial is to determine the benefit of the combination of nab-paclitaxel plus gemcitabine given for 6 cycles, followed by maintenance nab-paclitaxel alone, in patients with cisplatin-ineligible or cisplatin-incurable advanced urothelial carcinoma (UC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Florida Cancer Specialists - South, Fort Myers, Florida +4 locations
Conditions: Urothelial Carcinoma, Bladder Cancer, Transitional Cell Carcinoma
Register for Updates
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
NCT03742986
Completed
Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Indiana University, Bloomington, Indiana +1 locations
Conditions: Breast Cancer
Register for Updates
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
NCT02716038
Completed
This is a research study to test the effectiveness of nab-paclitaxel + carboplatin + MPDL3280A for treatment of non-small-cell lung carcinoma (NSCLC), which is a type of lung cancer. The study aims to determine if chemotherapy combined with immune-based therapy can lead to improvement in tumor response rates over historical response rates with chemotherapy alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
NCT01215136
Terminated
The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: University of Alabama Hematology Oncology Clinic at Medical West, Birmingham, Alabama +10 locations
Conditions: Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma
Register for Updates
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
NCT02672475
Completed
This phase I trial studies the side effects and best dose of Galunisertib when given together with paclitaxel in treating patients with androgen receptor negative or triple negative breast cancer that has spread to other places in the body. Some tumors need growth factors, which are made by the body's white blood cells, to keep growing. Galunisertib may interfere with growth factors and help cause tumor cells to die. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2023
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Register for Updates
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
NCT03189914
Completed
This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Rexahn Site, Tucson, Arizona +9 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates